^
    2d
    A Phase Ib/II Study Of JS015 Combination Therapy in Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=186, Recruiting, Shanghai Junshi Bioscience Co., Ltd. | Not yet recruiting --> Recruiting | Trial completion date: Apr 2026 --> Jan 2026
    Enrollment open • Trial completion date • Metastases
    |
    Avastin (bevacizumab) • gemcitabine • 5-fluorouracil • Loqtorzi (toripalimab-tpzi) • capecitabine • albumin-bound paclitaxel • oxaliplatin • irinotecan • leucovorin calcium
    2d
    CELAEC: Chemoradiation Versus Esophagectomy for Locally Advanced Esophageal Cancer (clinicaltrials.gov)
    P=N/A, N=196, Recruiting, The First Affiliated Hospital of Henan University of Science and Technology | Trial completion date: Jun 2021 --> Dec 2025 | Trial primary completion date: Dec 2020 --> Dec 2024
    Trial completion date • Trial primary completion date • Metastases
    |
    cisplatin • capecitabine • oxaliplatin
    3d
    XELOX Combined With Sintilimab and HBO for Advanced GC/GEJC (clinicaltrials.gov)
    P1/2, N=57, Not yet recruiting, West China Hospital
    New P1/2 trial • Metastases
    |
    Tyvyt (sintilimab) • capecitabine • oxaliplatin
    3d
    CB-839 + Capecitabine in Solid Tumors and Fluoropyrimidine Resistant PIK3CA Mutant Colorectal Cancer (clinicaltrials.gov)
    P1/2, N=50, Completed, David Bajor, MD | Active, not recruiting --> Completed
    Trial completion • Metastases
    |
    PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha)
    |
    PIK3CA mutation
    |
    capecitabine • telaglenastat (CB-839)
    3d
    SOLSTICE: Phase III Study in First-line Treatment of Patients With Metastatic Colorectal Cancer Who Are Not Candidate for Intensive Therapy. (clinicaltrials.gov)
    P3, N=856, Active, not recruiting, Institut de Recherches Internationales Servier | Trial completion date: Jun 2024 --> Dec 2025
    Trial completion date • Metastases
    |
    Avastin (bevacizumab) • capecitabine • Lonsurf (trifluridine/tipiracil)
    4d
    Perioperative Treatment of High-risk Resectable CCA with HAIC Plus A+T: Neobrave CCA (clinicaltrials.gov)
    P2, N=30, Not yet recruiting, Peking University
    New P2 trial
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • gemcitabine • 5-fluorouracil • capecitabine • oxaliplatin
    4d
    SurVIC: Upfront Surgery Vs Induction Chemotherapy Followed By Surgery In Oral Cancers: (clinicaltrials.gov)
    P3, N=346, Recruiting, All India Institute of Medical Sciences, Jodhpur
    New P3 trial • Surgery • Metastases
    |
    cisplatin • docetaxel • capecitabine
    6d
    Capecitabine regulates proliferation and apoptosis of ovarian cancer SKOV3 cells via the miR-29b-3p/MMP16 molecular axis. (PubMed, Am J Transl Res)
    Capecitabine enhances miR-29b-3p expression, leading to the downregulation of MMP16, thereby inhibiting proliferation and promoting apoptosis in ovarian cancer cells.
    Journal • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • CASP3 (Caspase 3) • MMP16 (Matrix Metallopeptidase 16)
    |
    BCL2 expression
    |
    capecitabine
    6d
    Addition of SHR-1701 to first-line capecitabine and oxaliplatin (XELOX) plus bevacizumab for unresectable metastatic colorectal cancer. (PubMed, Signal Transduct Target Ther)
    Elevated baseline lactate dehydrogenase was linked to shorter PFS. SHR-1701 combined with XELOX and bevacizumab demonstrated a manageable safety profile and potent antitumor activity in unresectable mCRC.
    Journal • Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker • Metastases
    |
    TMB (Tumor Mutational Burden) • TGFB1 (Transforming Growth Factor Beta 1)
    |
    TMB-H
    |
    capecitabine • oxaliplatin • retlirafusp alfa (SHR-1701) • Airuituo (bevacizumab biosimilar)
    6d
    ALTER-BC-005: Anlotinib-based Combination Therapy in Patients with Hormone Receptor-positive（HR+） Metastatic Breast Cancer(MBC) . (clinicaltrials.gov)
    P=N/A, N=80, Recruiting, Hunan Cancer Hospital
    New trial • Real-world evidence • Real-world • Metastases
    |
    Keytruda (pembrolizumab) • Focus V (anlotinib) • Tyvyt (sintilimab) • capecitabine • albumin-bound paclitaxel • fulvestrant • etoposide IV • Halaven (eribulin mesylate)
    9d
    TRIFLUOX-DP: Safety of Trifluridine/Tipiracil in Patients With Dihydropyrimidine Dehydrogenase Deficiency Diagnosed With Metastatic Colorectal or Gastroesophageal Cancer (clinicaltrials.gov)
    P2, N=73, Not yet recruiting, UNICANCER | Initiation date: Oct 2024 --> Jan 2025
    Trial initiation date • Metastases
    |
    Opdivo (nivolumab) • Avastin (bevacizumab) • Herceptin (trastuzumab) • 5-fluorouracil • Vectibix (panitumumab) • capecitabine • oxaliplatin • Lonsurf (trifluridine/tipiracil)
    9d
    All Trans Retinoic Acid Combined with Toripalimab+Chemotherapy for Locally Advanced Inoperable or Metastatic Triple Negative Breast Cancer：a Multi-center, Multi-cohort Phase II Trial (clinicaltrials.gov)
    P2, N=129, Recruiting, Fudan University | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    Loqtorzi (toripalimab-tpzi) • capecitabine • albumin-bound paclitaxel
    9d
    A Phase III Study of ESG401 for Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer (clinicaltrials.gov)
    P3, N=504, Not yet recruiting, Shanghai Escugen Biotechnology Co., Ltd
    New P3 trial • Metastases
    |
    carboplatin • capecitabine • albumin-bound paclitaxel • Halaven (eribulin mesylate) • ESG401
    9d
    Neo-Flo-Rect: Association Between the Composition of the Intestinal Microbiota and Tumor Response in Locally Advanced Rectal Cancer (clinicaltrials.gov)
    P=N/A, N=2, Terminated, Centre Oscar Lambret | Trial completion date: Sep 2026 --> Oct 2024 | Active, not recruiting --> Terminated | Trial primary completion date: Jan 2026 --> Oct 2024; Lack of eligible patients
    Trial completion date • Trial termination • Trial primary completion date • Metastases
    |
    capecitabine
    10d
    Updates in Treatment of HER2-positive Metastatic Breast Cancer. (PubMed, Curr Treat Options Oncol)
    The introduction of antibody-drug conjugates, in specific trastuzumab deruxtecan, has resulted in the best progression-free survival among patients with this subtype of breast cancer...Tucatinib, capecitabine, and trastuzumab combination represent one such promising strategy. With the increasing longevity of these patients, important clinical questions include optimal treatment sequencing, the role of de-escalation of treatment in excellent responders, and the associated financial toxicity. Despite the aggressive nature of this subtype of breast cancer, the outcomes continue to improve for these patients with the evolving treatments.
    Clinical • Observational data • Preclinical • Retrospective data • Review • Journal • PD(L)-1 Biomarker • IO biomarker • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • CDK4 (Cyclin-dependent kinase 4)
    |
    HER-2 positive • PIK3CA mutation • PD-L1 mutation
    |
    Enhertu (fam-trastuzumab deruxtecan-nxki) • capecitabine • Tukysa (tucatinib)
    10d
    Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer (clinicaltrials.gov)
    P3, N=726, Not yet recruiting, Daiichi Sankyo
    New P3 trial • Metastases
    |
    Keytruda (pembrolizumab) • cisplatin • Enhertu (fam-trastuzumab deruxtecan-nxki) • capecitabine • oxaliplatin
    10d
    OptiTROP-Breast01: SKB264 Injection Vs Investigator Selected Regimens to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer (clinicaltrials.gov)
    P3, N=254, Active, not recruiting, Sichuan Kelun Pharmaceutical Research Institute Co., Ltd. | Trial completion date: Dec 2024 --> Mar 2025
    Trial completion date • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
    |
    BRCA2 mutation • BRCA1 mutation • HER-2 negative • HER-2 expression • PGR negative • HER-2 negative + HR positive + BRCA mutation
    |
    gemcitabine • capecitabine • Halaven (eribulin mesylate) • vinorelbine tartrate • sacituzumab tirumotecan (MK-2870)
    10d
    CardioSwitch: Feasibility of Switching Fluoropyrimidine Due to Cardiotoxicity Study (clinicaltrials.gov)
    P=N/A, N=200, Enrolling by invitation, Helsinki University Central Hospital | Trial completion date: Dec 2025 --> Dec 2027 | Trial primary completion date: Dec 2020 --> Dec 2027
    Trial completion date • Trial primary completion date
    |
    5-fluorouracil • capecitabine • Lonsurf (trifluridine/tipiracil) • Teysuno (gimeracil/oteracil/tegafur)
    10d
    QUILT-3.060t: QUILT-3.060: NANT Pancreatic Cancer Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy (clinicaltrials.gov)
    P1/2, N=6, Terminated, ImmunityBio, Inc. | N=80 --> 6 | Unknown status --> Terminated; Study halted prematurely and will not resume; participants are no longer being examined or receiving intervention
    Enrollment change • Trial termination
    |
    Avastin (bevacizumab) • 5-fluorouracil • Bavencio (avelumab) • capecitabine • albumin-bound paclitaxel • cyclophosphamide • oxaliplatin • leucovorin calcium • Anktiva (nogapendekin alfa inbakicept-pmln) • ETBX-011 • GI-4000 • NK92-CD16-158V
    10d
    First-line Treatment with RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2) (clinicaltrials.gov)
    P2, N=110, Not yet recruiting, Qilu Hospital of Shandong University
    New P2 trial • Metastases
    |
    Herceptin (trastuzumab) • cisplatin • 5-fluorouracil • Tyvyt (sintilimab) • capecitabine • oxaliplatin • Aidixi (disitamab vedotin) • Teysuno (gimeracil/oteracil/tegafur)
    11d
    TORCH-G: Preoperative HFRT Verses PULSAR for Locally Advanced GEJ or Proximal Gastric Adenocarcinoma (clinicaltrials.gov)
    P2, N=68, Recruiting, Fudan University
    New P2 trial • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Tyvyt (sintilimab) • capecitabine • oxaliplatin
    11d
    FORTRESS: NG-350A Plus Chemoradiotherapy for Locally Advanced Rectal Cancer (clinicaltrials.gov)
    P1, N=30, Not yet recruiting, Akamis Bio | Initiation date: Nov 2024 --> Feb 2025
    Trial initiation date • Combination therapy • Metastases • Viral vector
    |
    capecitabine • NG-350A
    11d
    TUTOR: Tucatinib, Trastuzumab, and Capecitabine With SRS for Brain Metastases From HER-2 Positive Breast Cancer (clinicaltrials.gov)
    P1, N=40, Recruiting, Baptist Health South Florida | Trial completion date: Nov 2025 --> Feb 2029 | Trial primary completion date: Nov 2024 --> Feb 2028
    Trial completion date • Trial primary completion date • Surgery
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    Herceptin (trastuzumab) • capecitabine • Tukysa (tucatinib)
    11d
    QUILT-3.071: QUILT 3.071: NANT Colorectal Cancer (CRC) Vaccine (clinicaltrials.gov)
    P1/2, N=2, Terminated, ImmunityBio, Inc. | Phase classification: P1b/2 --> P1/2 | N=332 --> 2 | Active, not recruiting --> Terminated; low enrollment
    Phase classification • Enrollment change • Trial termination • Metastases
    |
    Erbitux (cetuximab) • 5-fluorouracil • Bavencio (avelumab) • capecitabine • albumin-bound paclitaxel • cyclophosphamide • Stivarga (regorafenib) • oxaliplatin • leucovorin calcium • Anktiva (nogapendekin alfa inbakicept-pmln) • ETBX-011 • ETBX-021 • ETBX-051 • ETBX-061 • GI-4000 • GI-6207 • GI-6301 • NK92-CD16-158V • aldoxorubicin (INNO-206)
    11d
    Alternating modified CAPOX/CAPIRI plus bevacizumab in untreated unresectable metastatic colorectal cancer: a phase 2 trial. (PubMed, Signal Transduct Target Ther)
    This phase 2 trial (NCT04324476) aimed to evaluate efficacy and safety of alternating modified CAPOX (capecitabine and oxaliplatin)/modified CAPIRI (capecitabine and irinotecan) plus bevacizumab (anti-VEGF-A antibody) in untreated unresectable mCRC...Thus, alternating modified CAPOX/CAPIRI plus bevacizumab had promising efficacy and acceptable safety. The regimen may be a novel option for untreated unresectable mCRC.
    P2 data • Journal • Metastases
    |
    RAS (Rat Sarcoma Virus)
    |
    RAS wild-type
    |
    Avastin (bevacizumab) • 5-fluorouracil • capecitabine • oxaliplatin • irinotecan • leucovorin calcium
    11d
    Precision medicine: an intrahepatic cholangiocarcinoma with a novel RBPMS-MET fusion sensitive to crizotinib. (PubMed, Oncologist)
    Our case report strengthens the evidence that crizotinib may be a viable treatment option for patients with ICC with a c-MET tyrosine kinase fusion, necessitating additional clinical investigation.
    Journal • PD(L)-1 Biomarker
    |
    MET (MET proto-oncogene, receptor tyrosine kinase) • RBPMS (RNA-binding protein with multiple splicing) • CA 19-9 (Cancer antigen 19-9)
    |
    MET fusion • RBPMS-MET fusion
    |
    Keytruda (pembrolizumab) • Xalkori (crizotinib) • gemcitabine • Lenvima (lenvatinib) • capecitabine
    12d
    ECOG-ACRIN EA2142: Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery (clinicaltrials.gov)
    P2, N=67, Active, not recruiting, ECOG-ACRIN Cancer Research Group | Trial primary completion date: Jan 2025 --> Jun 2025
    Trial primary completion date • Surgery • Metastases
    |
    cisplatin • carboplatin • temozolomide • capecitabine • etoposide IV
    12d
    POLESTAR: Chemotherapy and Pembrolizumab, Followed by Pembrolizumab and Olaparib as Firstline Therapy in Her-2 Negative Gastric/GEJ Adenocarcinoma (clinicaltrials.gov)
    P2, N=31, Active, not recruiting, Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Phase classification: P2a --> P2
    Phase classification
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)
    |
    HER-2 negative
    |
    Keytruda (pembrolizumab) • Lynparza (olaparib) • capecitabine • oxaliplatin
    12d
    Electroacupuncture Combined With Self-administered Acupressure for the Prevention of Capecitabine-Associated Hand-Foot Syndrome (clinicaltrials.gov)
    P=N/A, N=220, Recruiting, Affiliated Hospital of Qinghai University | Not yet recruiting --> Recruiting
    Enrollment open
    |
    capecitabine
    13d
    Sacituzumab Govitecan in Combination With Capecitabine for Advanced Gastrointestinal Cancers After Progression on Standard Therapy (clinicaltrials.gov)
    P1, N=20, Recruiting, Henry Ford Health System | Not yet recruiting --> Recruiting
    Enrollment open • Combination therapy • Metastases
    |
    TACSTD2 (Tumor Associated Calcium Signal Transducer 2)
    |
    capecitabine • Trodelvy (sacituzumab govitecan-hziy)
    13d
    Phase II Clinical Study of AC591 in Preventing Oxaliplatin-Induced Peripheral Neuropathy (clinicaltrials.gov)
    P2, N=120, Not yet recruiting, Shandong New Time Pharmaceutical Co., LTD
    New P2 trial
    |
    capecitabine • oxaliplatin
    13d
    Serplulimab Combined with CAPEOX + Celecoxib As Neoadjuvant Treatment for Locally Advanced Rectal Cancer (clinicaltrials.gov)
    P2, N=50, Recruiting, Zhejiang University | Trial completion date: Feb 2025 --> Dec 2025 | Trial primary completion date: Feb 2024 --> Dec 2025
    Trial completion date • Trial primary completion date • Metastases
    |
    capecitabine • oxaliplatin • Hetronifly (serplulimab) • celecoxib oral
    16d
    The application of immunotherapy combined with taxanes in second‑line treatment of advanced HER2 negative gastric cancer. (PubMed, Mol Clin Oncol)
    A total of 21 patients with advanced HER2-negative GC, who had progressed after receiving standard first-line regimens [tegafur, gimeracil and oteracil potassium capsules (S-1) or capecitabine plus oxaliplatin], were selected. The present study retrospectively analyzed the new second-line approach of PD-1 inhibitor combined with taxanes for HER2 negative GC which effectively improved patient PFS and OS compared with single-agent chemotherapy. The expression levels of Ki67 and the tumor marker-negative status possess potential clinical value in monitoring prognosis and guiding future individualized use of chemotherapy combined with immunotherapy.
    Journal • PD(L)-1 Biomarker • IO biomarker • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • MUC16 (Mucin 16, Cell Surface Associated) • CA 19-9 (Cancer antigen 19-9)
    |
    HER-2 negative
    |
    capecitabine • oxaliplatin • Teysuno (gimeracil/oteracil/tegafur)
    16d
    Testing Immunotherapy (Atezolizumab) With or Without Chemotherapy in Locoregional MSI-H/dMMR Gastric and Gastroesophageal Junction (GEJ) Cancer (clinicaltrials.gov)
    P2, N=240, Active, not recruiting, National Cancer Institute (NCI) | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    MSI (Microsatellite instability) • MLH1 (MutL homolog 1) • MSH6 (MutS homolog 6) • MSH2 (MutS Homolog 2)
    |
    MSI-H/dMMR • MSH6 expression
    |
    Tecentriq (atezolizumab) • docetaxel • capecitabine • oxaliplatin • leucovorin calcium • fluorouracil topical
    17d
    A non-inferiority, phase III trial of gemcitabine plus capecitabine versus gemcitabine plus carboplatin as first-line therapy and tumor-infiltrating lymphocytes as a prognostic biomarker in patients with advanced triple-negative breast cancer. (PubMed, Ther Adv Med Oncol)
    However, the GX regimen should be considered in patients who cannot tolerate hematological toxicity. ClinicalTrials.gov identifier: NCT02207335.
    P3 data • Journal • Head-to-Head • Tumor-infiltrating lymphocyte • Metastases
    |
    CD8 (cluster of differentiation 8)
    |
    CD8-H
    |
    carboplatin • gemcitabine • capecitabine
    17d
    Targeted and cytotoxic inhibitors used in the treatment of breast cancer. (PubMed, Pharmacol Res)
    Hormonal or endocrine therapy includes selective estrogen receptor modulators (SERMs) such as raloxifene, tamoxifen and toremifene, selective estrogen-receptor degraders (SERDs) including elacestrant and fulvestrant, and aromatase inhibitors such as anastrozole, letrozole, and exemestane...These agents include taxanes (docetaxel, nab-paclitaxel, and paclitaxel), anthracyclines (doxorubicin, epirubicin), anti-metabolites (capecitabine, gemcitabine, fluorouracil, methotrexate), alkylating agents (carboplatin, cisplatin, and cyclophosphamide), and drugs that target microtubules (eribulin, ixabepilone, ado-trastuzumab emtansine). Patients with ER-positive tumors are treated with 5-10 years of endocrine therapy and chemotherapy. For patients with metastatic breast cancer, standard first-line and follow-up therapy options include targeted approaches such as CDK4/6 inhibitors, PI3K inhibitors, PARP inhibitors, and anti-PDL1 immunotherapy, depending on the tumor type and molecular profile.
    Review • Journal • BRCA Biomarker • PARP Biomarker • PD(L)-1 Biomarker • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • PGR (Progesterone receptor) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
    |
    HER-2 positive • ER positive • HR positive • HER-2 negative • HR positive + HER-2 negative • HER-2 negative + ER positive • HER-2 negative + HR negative • HER-2 positive + HR negative
    |
    cisplatin • carboplatin • gemcitabine • docetaxel • 5-fluorouracil • tamoxifen • Kadcyla (ado-trastuzumab emtansine) • doxorubicin hydrochloride • capecitabine • albumin-bound paclitaxel • cyclophosphamide • fulvestrant • Halaven (eribulin mesylate) • methotrexate • letrozole • epirubicin • anastrozole • exemestane • Orserdu (elacestrant) • Ixempra (ixabepilone) • raloxifene hydrochloride
    17d
    GO30103: Safety and Pharmacokinetics (PK) of Escalating Doses of Tiragolumab as a Single Agent and in Combination With Atezolizumab and/or Other Anti-Cancer Therapies in Locally Advanced or Metastatic Tumors (clinicaltrials.gov)
    P1, N=518, Completed, Genentech, Inc. | Active, not recruiting --> Completed
    Trial completion • Combination therapy • Metastases
    |
    Keytruda (pembrolizumab) • Avastin (bevacizumab) • cisplatin • Tecentriq (atezolizumab) • carboplatin • paclitaxel • capecitabine • pemetrexed • etoposide IV • tiragolumab (RG6058)
    17d
    A Clinical Trial to Evaluate Effect of IAE0972 Combined with Chemotherapy for R/M HNSCC or NPC(Note: It is Currently Phase II.). (clinicaltrials.gov)
    P2/3, N=60, Not yet recruiting, SUNHO（China）BioPharmaceutical CO., Ltd.
    New P2/3 trial • Metastases
    |
    gemcitabine • docetaxel • capecitabine • IAE0972
    17d
    Toripalimab Combined With Capecitabine as Postoperative Adjuvant Therapy for Patients With Resectable Advanced Extrahepatic Biliary Tract Cancer (clinicaltrials.gov)
    P2, N=110, Active, not recruiting, Tianjin Medical University Cancer Institute and Hospital
    New P2 trial • Metastases
    |
    Loqtorzi (toripalimab-tpzi) • capecitabine
    18d
    CAPPA: Capecitabine Plus Pembrolizumab in Patients With Triple Negative Breast Cancer After Chemo-immunotherapy and Surgery (clinicaltrials.gov)
    P2, N=220, Not yet recruiting, UNICANCER | Phase classification: P3 --> P2 | N=418 --> 220 | Trial completion date: Jan 2029 --> Jun 2028 | Trial primary completion date: Jan 2026 --> Jun 2028
    Phase classification • Enrollment change • Trial completion date • Trial primary completion date • Surgery
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative
    |
    Keytruda (pembrolizumab) • capecitabine
    19d
    The Efficacy and Safety of Mecobalamin in the Prevention of Capecitabine Induced Hand Foot Syndrome (clinicaltrials.gov)
    P3, N=234, Active, not recruiting, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2025 --> Aug 2024
    Enrollment closed • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    capecitabine
    19d
    Neoadjuvant Safety of Sintilimab + XELOX + Bevacizumab in PMMR/MSS CRLM Patients (clinicaltrials.gov)
    P1/2, N=36, Active, not recruiting, Sun Yat-sen University | Trial completion date: Oct 2024 --> Oct 2025
    Trial completion date
    |
    Avastin (bevacizumab) • Tyvyt (sintilimab) • capecitabine • oxaliplatin